GuidelineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2014
SEOM clinical guidelines for the treatment of renal cell carcinoma.
Guideline in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.The oncologist · 2017Pooled it
- Development and Validation of a Competitive Risk Model in Elderly Patients With Chromophobe Cell Renal Carcinoma: A Population-Based Study.Frontiers in public health · 2022Trial
- Simultaneous laparoscopic management of dual primary malignancies: case reports and literature review of synchronous renal cell carcinoma and colon carcinoma of sigmoid.Journal of surgical case reports · 2025Article
- Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- A nomogram for predicting cancer-specific survival and overall survival in elderly patients with nonmetastatic renal cell carcinoma.Frontiers in surgery · 2022Article
- The Critical Gene Screening to Prevent Chromophobe Cell Renal Carcinoma Metastasis through TCGA and WGCNA.Journal of oncology · 2022Article
- Heterogeneity in NK Cell Subpopulations May Be Involved in Kidney Cancer Metastasis.Journal of immunology research · 2022Article
- Correlation among different pathologic features of renal cell carcinoma: a retrospective analysis of 249 cases.International journal of clinical and experimental pathology · 2020Article
- Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma.Oncotarget · 2017Article
- Antiangiogenics and immunotherapies in cervical cancer: an update and future's view.Medical oncology (Northwood, London, England) · 2017Review
- Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report.Molecular and clinical oncology · 2017Article
- Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient.Frontiers in pharmacology · 2017Article
- Review of renal cell carcinoma and its common subtypes in radiology.World journal of radiology · 2016Review
- Two cases of gallbladder metastasis from renal cell carcinoma and review of literature.World journal of surgical oncology · 2016Article
- Renal Cancer in the Elderly.Current urology reports · 2016Review
- Sequence of treatment in locally advanced and metastatic renal cell carcinoma.Translational andrology and urology · 2015Review
- Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition.Oncotarget · 2015Article
- Familial syndromes associated with neuroendocrine tumours.Contemporary oncology (Poznan, Poland) · 2015Review
- SEOM guidelines 2014: improving quality to increase its usefulness.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this article was to provide updated recommendations for the diagnosis and treatment of renal cell carcinoma. Pathological confirmation is mandatory before treatment with ablative or focal therapies before any type of systemic therapy. Renal cell cancer should be staged according to the TNM classification system. A laparoscopic nephron-sparing surgery should be the approach for tumors <4 cm if technically feasible. Otherwise, radical (or partial in selected cases) nephrectomy is the treatment of choice, with lymph node dissection only performed in patients with clinically detected lymph node involvement. Some retrospective evidence for a cytoreductive nephrectomy in the postimmunotherapy era suggests a benefit in patients with good or intermediate risk or for patients with a symptomatic primary lesion. Adjuvant treatment with chemotherapy or with targeted agents is not recommended and studies are ongoing today. Patients with metastatic disease should be staged by computed tomography scans of the chest, abdomen and pelvis. The efficacy of sunitinib, bevacizumab plus interferon-α, and pazopanib is well established in patients with good and intermediate risk as well for temsirolimus in poor-risk patients. These four agents are considered standard of care in first-line treatment. Sorafenib, axitinib and everolimus are standard of care in second line in different settings based on their benefit in PFS. Besides some benefit described for IL-2 in highly selected patients in first line, there is a promising and emerging role for the new immunotherapeutic approaches in metastatic renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.